Pancreatic Cancer Research

ResearcherIndiana University HealthActive in the last 2 years

Michele Yip-Schneider

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7569-7971; OpenAlex author ID A5051059014. Sources: OpenAlex.

Their work

Papers
15 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
49
Papers, trials and grants by year

2012: 1 paper · 2013: 3 papers · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 2 papers

Papers 15

  1. Lead time trajectory of blood-based protein biomarkers for detection of pancreatic cancer based on repeat testing. First author DOI 10.1016/j.canlet.2025.217450↗
  2. Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progress… Co-author DOI 10.1158/1078-0432.ccr-24-2931↗
  3. Contributions of the Microbiome-Derived Metabolome for Risk Assessment and Prognostication of Pancreatic Cancer. Co-author DOI 10.1093/clinchem/hvad186↗
  4. Potential Health Disparities in the Early Detection and Prevention of Pancreatic Cancer. Co-author DOI 10.7759/cureus.60240↗
  5. Amplification-Free, High-Throughput Nanoplasmonic Quantification of Circulating MicroRNAs in Unprocessed Plasma Microsamples for Earlier Pancreatic Cancer Dete… Co-author DOI 10.1021/acssensors.2c02105↗
  6. Integrated spatial transcriptomics and lipidomics of precursor lesions of pancreatic cancer identifies enrichment of long chain sulfatide biosynthesis as an ea… Co-author DOI 10.1101/2023.08.14.553002↗
  7. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Co-author DOI 10.1053/j.gastro.2020.11.052↗
  8. Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression? Co-author DOI 10.1016/j.amjsurg.2019.09.013↗
  9. Discussion on: Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression? Co-author DOI 10.1016/j.amjsurg.2020.02.014↗
  10. A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. Co-author DOI 10.1093/jnci/djy126↗
  11. Factors influencing the cytotoxicity of α-methylene-γ-hydroxy esters against pancreatic cancer. Last author DOI 10.1016/j.bmcl.2015.07.087↗
  12. Synthetic α-(aminomethyl)-γ-butyrolactones and their anti-pancreatic cancer activities. Last author DOI 10.1016/j.bmcl.2013.09.065↗
  13. Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e318254f455↗
  14. Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. Co-author DOI 10.1186/1471-2407-13-194↗
  15. Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells. First author DOI 10.1007/s11605-012-1913-7↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christian Max Schmidt · 12 shared papers, 2012–2025 · strength 1.20
  2. Jody V. Vykoukal · 6 shared papers, 2019–2025 · strength 0.91
  3. Johannes Francois Fahrmann · 6 shared papers, 2019–2025 · strength 0.91
  4. Jianjun Zhang · 6 shared papers, 2019–2025 · strength 0.91
  5. Samir Hanash · 6 shared papers, 2019–2025 · strength 0.91
  6. Anirban Maitra · 6 shared papers, 2019–2025 · strength 0.91
  7. Ehsan Irajizad · 5 shared papers, 2021–2025 · strength 0.84
  8. Christopher M. Schmidt · 3 shared papers, 2020–2025 · strength 0.59
  9. Ricardo A. Léon-Letelier · 3 shared papers, 2023–2025 · strength 0.52
  10. Yihui Chen · 2 shared papers, 2023–2025 · strength 0.33
  11. Rosalie A. Carr · 2 shared papers, 2020 · strength 0.26
  12. Katelyn F. Flick · 2 shared papers, 2020 · strength 0.26
  13. Alexandra M. Roch · 1 shared paper, 2024 · strength 0.23
  14. Rachel C. Kim · 1 shared paper, 2024 · strength 0.23
  15. Riccardo Ballarò · 1 shared paper, 2025 · strength 0.19
  16. Melissa L. Fishel · 1 shared paper, 2023 · strength 0.17
  17. Nayela N. Chowdhury · 1 shared paper, 2023 · strength 0.17
  18. Adrianna N. Masterson · 1 shared paper, 2023 · strength 0.17
  19. Rajesh Sardar · 1 shared paper, 2023 · strength 0.17
  20. Fredrik I. Thege · 1 shared paper, 2023 · strength 0.13
  21. Jimin Min · 1 shared paper, 2023 · strength 0.13
  22. Robert A. Wolff · 1 shared paper, 2023 · strength 0.13
  23. Paola A. Guerrero · 1 shared paper, 2023 · strength 0.13
  24. Marta Sans · 1 shared paper, 2023 · strength 0.13
  25. Michael P. Kim · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.